Your browser is no longer supported. Please, upgrade your browser.
Settings
INCY Incyte Corporation daily Stock Chart
INCY [NASD]
Incyte Corporation
IndexS&P 500 P/E169.98 EPS (ttm)0.50 Insider Own0.30% Shs Outstand213.02M Perf Week0.91%
Market Cap18.25B Forward P/E29.61 EPS next Y2.89 Insider Trans-15.03% Shs Float212.87M Perf Month1.81%
Income109.50M PEG3.70 EPS next Q0.41 Inst Own94.50% Short Float2.38% Perf Quarter29.31%
Sales1.88B P/S9.70 EPS this Y133.20% Inst Trans0.80% Short Ratio3.27 Perf Half Y25.82%
Book/sh9.04 P/B9.48 EPS next Y46.63% ROA4.40% Target Price89.33 Perf Year-4.84%
Cash/sh6.75 P/C12.69 EPS next 5Y46.00% ROE6.20% 52W Range57.00 - 89.75 Perf YTD34.72%
Dividend- P/FCF69.47 EPS past 5Y23.80% ROI6.30% 52W High-4.55% Beta1.39
Dividend %- Quick Ratio4.30 Sales past 5Y39.60% Gross Margin96.10% 52W Low50.30% ATR1.88
Employees1367 Current Ratio4.30 Sales Q/Q19.00% Oper. Margin6.90% RSI (14)57.44 Volatility1.81% 2.27%
OptionableYes Debt/Eq0.01 EPS Q/Q145.10% Profit Margin5.80% Rel Volume0.54 Prev Close85.62
ShortableYes LT Debt/Eq0.01 EarningsFeb 14 BMO Payout0.00% Avg Volume1.55M Price85.67
Recom2.00 SMA200.95% SMA505.60% SMA20021.15% Volume837,961 Change0.06%
Jan-24-19Upgrade William Blair Mkt Perform → Outperform
Jan-24-19Upgrade Gabelli & Co Hold → Buy $105
Jan-16-19Downgrade UBS Buy → Neutral
Jan-03-19Upgrade Guggenheim Neutral → Buy
Oct-22-18Upgrade Raymond James Outperform → Strong Buy
Oct-01-18Initiated Cantor Fitzgerald Neutral $73
Sep-25-18Initiated Leerink Partners Mkt Perform
Aug-15-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Aug-01-18Downgrade JMP Securities Mkt Outperform → Mkt Perform
Jul-13-18Downgrade Morgan Stanley Overweight → Equal-Weight
Jun-26-18Downgrade RBC Capital Mkts Outperform → Sector Perform
Jun-11-18Upgrade Evercore ISI In-line → Outperform
Apr-09-18Reiterated Credit Suisse Outperform $145 → $78
Apr-09-18Downgrade Gabelli & Co Buy → Hold
Apr-06-18Downgrade William Blair Outperform → Mkt Perform
Apr-06-18Downgrade Guggenheim Buy → Neutral
Apr-05-18Reiterated Barclays Overweight $165 → $135
Jan-02-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Nov-21-17Reiterated RBC Capital Mkts Sector Perform $136 → $120
Oct-06-17Resumed Goldman Buy $160
Mar-16-19 09:30AM  Why Is Incyte (INCY) Up 1.7% Since Last Earnings Report? Zacks
Mar-14-19 10:55AM  Agenus Inc (AGEN) Q4 2018 Earnings Conference Call Transcript Motley Fool
08:45AM  Zacks.com featured expert Kevin Matras highlights: Incyte, AMC Entertainment, Covanta and U.S. Silica Zacks
Mar-13-19 10:55AM  10 Stocks Powering S&P 500 ETF in the 10-Year Bull Run Zacks
09:45AM  4 Toxic Stocks to Abandon or Sell Short for Solid Gains Zacks
Mar-08-19 01:40PM  Why Incyte Corporation (NASDAQ:INCY) Is A Financially Healthy Company Simply Wall St.
Mar-06-19 05:50PM  More biotech takeover targets coming, says Jefferies top analyst CNBC Videos
06:42AM  Pullback Strategies: 10 Stocks That Could Fall the Fastest Investopedia
Mar-05-19 08:42AM  Merck Gets CHMP Nod for Six-Week Dosing Option of Keytruda Zacks
05:00AM  Incyte- Insights into Small Molecule Drugs MoneyShow
Mar-01-19 07:00AM  New Research Coverage Highlights Nasdaq, Constellation Brands, Incyte, IMAX, HNI, and Frank's International N.V Consolidated Revenues, Company Growth, and Expectations for 2019 GlobeNewswire
Feb-28-19 10:30AM  Incyte Joins Patient Organizations Worldwide in Recognizing Rare Disease Day 2019 Business Wire
08:00AM  Data from Incytes Cancer Research Portfolio to be Featured in Seven Abstracts at the AACR Annual Meeting 2019 Business Wire
Feb-27-19 09:27AM  Zacks.com featured expert Kevin Matras highlights: First Majestic Silver, Incyte, Covanta and U.S. Silica Zacks
07:25AM  3 Big Stock Charts for Wednesday: Cabot Oil & Gas, Incyte and Sempra Energy InvestorPlace
12:06AM  Macrogenics Inc (MGNX) Q4 2018 Earnings Conference Call Transcript Motley Fool
Feb-26-19 09:26AM  4 Toxic Stocks to Discard or Sell Short for Solid Gains Zacks
Feb-21-19 11:25AM  Looking For Growth? Take A Look At These Biotechnology Stocks Investor's Business Daily
09:12AM  Merck Gets Priority Review for Keytruda in Third-Line SCLC Zacks
Feb-20-19 12:45PM  6 Companies With 20% Or More Earnings Growth Investopedia
08:39AM  Merck's Keytruda Fails to Meet Endpoint in Liver Cancer Study Zacks
Feb-19-19 09:02AM  Merck's (MRK) Stock Up Almost 50% in a Year: Here's Why Zacks
08:00AM  Incyte to Present at Upcoming Investor Conferences Business Wire
Feb-18-19 08:10AM  Merck Gets Priority Review for Keytruda Combo in Kidney Cancer Zacks
07:00AM  Incyte's Undervalued as Pipeline Progresses Morningstar
05:10AM  Edited Transcript of INCY earnings conference call or presentation 14-Feb-19 1:00pm GMT Thomson Reuters StreetEvents
Feb-14-19 09:25PM  Incyte (INCY) Q4 2018 Earnings Conference Call Transcript Motley Fool
04:11PM  Highly Rated Biotech Turns Profitable But Earnings Lag Estimates Investor's Business Daily
01:49PM  Incyte (INCY) Q4 Earnings Miss Estimates, Revenues Beat Zacks
10:38AM  Biotech Hedge Fund Bailed on Drugmaker Before Its Depression Treatment Scored Bloomberg
08:20AM  Incyte (INCY) Q4 Earnings Lag Estimates Zacks
07:26AM  Incyte: 4Q Earnings Snapshot Associated Press
07:00AM  Incyte Reports 2018 Fourth Quarter and Year-End Financial Results, Provides 2019 Financial Guidance and Provides Updates on Key Clinical Programs Business Wire
02:02AM  Incyte Earnings, Revenue beat in Q4 Investing.com
Feb-13-19 05:22PM  Incyte Expected to Earn 17 Cents a Share TheStreet.com
03:34PM  Biotech Stock Roundup: Regeneron Impresses in Q4, Gilead Slumps, MacroGenics Soars Zacks
Feb-12-19 09:24AM  Zacks.com featured highlights include: Incyte, First Majestic, Mattel and U.S. Silica Zacks
09:12AM  Merck's Keytruda Gets FDA Priority Review for Head/Neck Cancer Zacks
Feb-11-19 03:58PM  Is a Disappointment in Store for Incyte (INCY) Q4 Earnings? Zacks
08:58AM  4 Toxic Stocks to Abandon or Sell Short for Solid Gains Zacks
08:45AM  Why Incyte Stock Gained 27% in January Motley Fool
Feb-08-19 04:33PM  Incyte Down as FDA Extends Review Period of Jakafi for GVHD Zacks
Feb-07-19 04:23PM  FDA Delays This Biotech's Drug Why Analysts Are Still Bullish Investor's Business Daily
11:18AM  FDA resets decision date on Incyte's GVHD treatment application American City Business Journals
07:00AM  Incyte Announces U.S. FDA Has Extended the Review Period for Ruxolitinib (Jakafi®) in Acute Graft-Versus-Host Disease Business Wire
Feb-06-19 06:16PM  MacroGenics stock spikes from positive results of cancer drug trial American City Business Journals
Feb-05-19 08:07AM  Lilly/Incyte's Olumiant Meets Endpoint in Eczema Studies Zacks
Feb-04-19 06:45AM  Lilly Announces Top-Line Phase 3 Results for Baricitinib in Patients with Moderate to Severe Atopic Dermatitis PR Newswire
Jan-30-19 09:15AM  Dow Pushes Forward Under Apple's Shadow Zacks
Jan-29-19 07:25AM  Report: Developing Opportunities within Incyte, Burlington Stores, Hannon Armstrong Sustainable Infrastructure Capital, iRobot, Lear, and Menlo Therapeutics Future Expectations, Projections Moving into 2019 GlobeNewswire
Jan-28-19 10:22AM  Zacks.com featured highlights include: Incyte, KEYW, First Majestic and Mattel Zacks
08:00AM  Today's Research Reports on Trending Tickers: Incyte and Repligen ACCESSWIRE
07:48AM  3 Big Stock Charts for Monday: Pfizer, MGM Resorts and Incyte InvestorPlace
Jan-25-19 03:07PM  Moving Average Can Give Early Signals Of Trouble Investor's Business Daily
08:54AM  4 Toxic Stocks to Get Rid Off or Sell Short for Solid Gains Zacks
Jan-24-19 08:00AM  Incyte to Report Fourth Quarter and Year-end Financial Results Business Wire
Jan-23-19 09:12AM  Biotech Stock Roundup: Amgen, Vertex Get EC Nod for Label Expansion of Drugs Zacks
Jan-22-19 01:24PM  Should You Take Comfort From Insider Transactions At Incyte Corporation (NASDAQ:INCY)? Simply Wall St.
07:30AM  Incyte Announces First Patient Treated in Phase 3 Clinical Trial of Itacitinib for Chronic Graft-Versus-Host Disease Business Wire
Jan-16-19 08:00AM  Today's Research Reports on Trending Tickers: Incyte and CorMedix ACCESSWIRE
Jan-15-19 04:48PM  Heres your guide to the upcoming biotechnology takeover wave MarketWatch +7.10%
04:19PM  Why Yet Another Biotech Stock Is Grabbing Renewed Takeover Chatter Investor's Business Daily
01:36PM  FANG Stocks, Cyclicals Lead Nasdaq, Dow Jones Up; This Sector Is Poised To Rally More Investor's Business Daily
Jan-14-19 08:39AM  What's in Store for Merck in 2019 After a Solid Run in '18? Zacks
Jan-11-19 09:04AM  3 Biotech Stocks Bubbling Away Investopedia
Jan-08-19 08:56AM  4 Biotechs That Are Potential Buyouts Post Celgene Deal Zacks
Jan-07-19 12:17PM  Why Agenus Stock Is Spiking Today Motley Fool
07:00AM  Merus Announces IND Clearance for MCLA-145 GlobeNewswire
Jan-04-19 07:26AM  3 Big Stock Charts for Friday: Incyte, Schlumberger and Abbott Laboratories InvestorPlace +6.19%
06:17AM  Merck Buys NASH Candidate, Keytruda Wins 5 Approvals in Japan Zacks
Jan-03-19 05:46PM  Factbox - Bristol-Myers' $74 billion Celgene buy has investors looking for next deal Reuters +7.08%
04:31PM  Why Celgene, Agenus, and Incyte Jumped Today Motley Fool
03:15PM  Incyte Climbs on Guggenheim Upgrade TheStreet.com
07:00AM  Incyte Appoints Christiana Stamoulis as Chief Financial Officer Business Wire
Dec-21-18 08:57AM  Merck's sBLA for Keytruda in Lung Cancer Gets Extended Review Zacks
Dec-20-18 04:30PM  Incyte Announces First Patient Treated in Phase 3 Clinical Trial Program for Ruxolitinib Cream in Atopic Dermatitis Business Wire
10:13AM  The Zacks Analyst Blog Highlights: Amgen, Aduro, Vertex, Evofem and Incyte Zacks
Dec-19-18 09:17AM  Biotech Stock Roundup: Pipeline Updates From VRTX & AMGN, ADRO Teams Up With LLY Zacks
Dec-18-18 09:37AM  Here Are Biotechs Big Pipeline Disappointments in 2018 Motley Fool
09:24AM  Immuno-Oncology Suffered a Setback in 2018. Whats Next? Motley Fool
Dec-17-18 02:53PM  Incyte (INCY) Collaborates with Innovent for 3 Candidates Zacks
09:44AM  Incyte enters into potential $391M collaboration with Chinese biopharm firm American City Business Journals
Dec-16-18 08:22PM  Innovent, Incyte Announce Strategic Collaboration, Licensing Agreement for Three Clinical-stage Product Candidates in China; Incyte to Receive $40M Upfront; Up to $331M in Regulatory and Commercial Milestones Benzinga
05:48PM  BRIEF-Innovent, Incyte Announce Strategic Collaboration And Licensing Agreement Reuters
05:40PM  Innovent and Incyte Announce Strategic Collaboration and Licensing Agreement for Three Clinical-stage Product Candidates in China Business Wire
05:35PM  Innovent and Incyte Announce Strategic Collaboration and Licensing Agreement for Three Clinical-stage Product Candidates in China PR Newswire
Dec-14-18 10:50AM  Global fears strike Wall Street Yahoo Finance
07:59AM  5 Biotech Stocks Set to Bounce Back in '19 After a Rough Ride Zacks
Dec-13-18 10:13AM  Top 10 Healthcare Stories of 2018 Motley Fool
08:00AM  Incyte to Present at Upcoming Investor Conferences Business Wire
06:45AM  FDA Grants Fast Track Designation to the Baricitinib Development Program for the Treatment of Systemic Lupus Erythematosus (SLE) PR Newswire
Dec-12-18 08:56AM  Roche to Create Companion Diagnostic Test for Merck's Keytruda Zacks
Dec-10-18 03:45PM  Why MacroGenics Stock Is Getting Hammered Today Motley Fool
07:58AM  5 Top Drug/Biotech Merger & Acquisition Targets for 2019 Zacks
Dec-06-18 09:20AM  Shire (SHPG), Takeda Shareholders Approve $62 Billion Merger Zacks
Dec-04-18 05:25PM  Incyte (INCY) Announces Positive Data on Jakafi for GVHD Zacks
07:00AM  Today's Research Reports on Trending Tickers: Incyte and Supernus Pharmaceuticals ACCESSWIRE
Dec-03-18 10:00AM  Results of REACH1 Study of Ruxolitinib (Jakafi®) for the Treatment of Acute Graft-Versus-Host Disease Demonstrate Rapid and Durable Patient Benefit Business Wire +6.33%
Dec-02-18 05:51PM  The Week Ahead In Biotech: ASH Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs Benzinga
Nov-29-18 09:31AM  Why Is Incyte (INCY) Up 1.5% Since Last Earnings Report? Zacks
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug in Phase III clinical trial for steroid-refractory acute graft-versus-host-diseases (GVHD); and Phase II trial for the treatment of essential thrombocythemia and refractory myelofibrosis. In addition, the company engages in the development of itacitinib, which is in Phase III clinical trial to treat naive acute and chronic GVHD, as well as Phase I/II clinical trial in combination with osimertinib for non-small cell lung cancer (NSCLC); and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, and 8p11 myeloproliferative syndrome, as well as a pivotal program for solid tumors with driver activations of FGF/FGFR. Further, it is involved in developing INCMGA0012 that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer. Additionally, the company develops Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Jiangsu Hengrui Medicine Co., Ltd.; Merus N.V.; Calithera Biosciences, Inc; MacroGenics, Inc.; Syros Pharmaceuticals, Inc.; and Innovent Biologics, Inc. The company was founded in 1991 and is headquartered in Wilmington, Delaware.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SWAIN PAULA JEVP, Human ResourcesMar 01Option Exercise18.3210,000183,20046,513Mar 05 04:45 PM
SWAIN PAULA JEVP, Human ResourcesMar 01Sale86.6810,000866,80036,513Mar 05 04:45 PM
BAKER BROS. ADVISORS LPDirectorFeb 26Option Exercise2.8040,000112,00029,288,793Feb 27 05:19 PM
SWAIN PAULA JEVP, Human ResourcesFeb 01Option Exercise18.3210,000183,20041,124Feb 05 04:36 PM
SWAIN PAULA JEVP, Human ResourcesFeb 01Sale81.1910,000811,90031,124Feb 05 04:36 PM
Flannelly Barry PEVP & General Manager USJan 28Sale80.001,00080,0008,944Jan 30 04:22 PM
Wenqing YaoEVP, Head of Discovery ChemJan 17Option Exercise17.7915,354273,14849,763Jan 22 06:04 PM
Wenqing YaoEVP, Head of Discovery ChemJan 17Sale77.6115,3541,191,62434,409Jan 22 06:04 PM
Trower PaulPrincipal Accounting OfficerJan 15Option Exercise17.795,813103,41319,713Jan 17 04:15 PM
Trower PaulPrincipal Accounting OfficerJan 15Sale75.005,813435,97513,900Jan 17 04:15 PM
Flannelly Barry PEVP & General Manager USJan 08Sale75.561,714129,5109,944Jan 10 04:11 PM
Trower PaulPrincipal Accounting OfficerJan 07Option Exercise17.799,187163,43723,359Jan 08 04:42 PM
Wenqing YaoEVP, Head of Discovery ChemJan 07Option Exercise17.7910,000177,90045,217Jan 08 04:46 PM
Trower PaulPrincipal Accounting OfficerJan 07Sale75.009,187689,02514,172Jan 08 04:42 PM
Wenqing YaoEVP, Head of Discovery ChemJan 07Sale75.0010,000750,00035,217Jan 08 04:46 PM
SWAIN PAULA JEVP, Human ResourcesJan 04Option Exercise18.3230,000549,60062,324Jan 08 04:37 PM
SWAIN PAULA JEVP, Human ResourcesJan 04Sale70.0030,0002,100,00032,324Jan 08 04:37 PM
BIENAIME JEAN JACQUESDirectorNov 08Buy68.771,00068,7656,668Nov 09 04:21 PM
SWAIN PAULA JEVP, Human ResourcesOct 03Option Exercise18.3210,000183,20042,324Oct 05 04:29 PM
Trower PaulPrincipal Accounting OfficerOct 03Option Exercise17.7910,000177,90024,172Oct 05 04:30 PM
Trower PaulPrincipal Accounting OfficerOct 03Sale70.0010,000700,00014,172Oct 05 04:30 PM
SWAIN PAULA JEVP, Human ResourcesOct 03Sale70.0010,000700,00032,324Oct 05 04:29 PM
Flannelly Barry PEVP & General Manager USOct 03Sale70.001,00070,00012,427Oct 05 04:23 PM
SWAIN PAULA JEVP, Human ResourcesSep 04Option Exercise18.3210,000183,20042,324Sep 06 04:30 PM
SWAIN PAULA JEVP, Human ResourcesSep 04Sale73.2110,000732,10032,324Sep 06 04:30 PM
SWAIN PAULA JEVP, Human ResourcesAug 21Option Exercise18.3210,000183,20042,324Aug 22 04:02 PM
SWAIN PAULA JEVP, Human ResourcesAug 21Sale70.0010,000700,00032,324Aug 22 04:02 PM
SWAIN PAULA JEVP, Human ResourcesJul 09Option Exercise18.3210,000183,20042,963Jul 11 04:41 PM
SWAIN PAULA JEVP, Human ResourcesJul 09Sale71.1110,000711,10032,963Jul 11 04:41 PM
Iyengar Vijay KEVP GPS, BD, & LicensingJul 09Sale71.3460643,2328,103Jul 11 04:39 PM
BROOKE PAUL ADirectorJun 04Option Exercise2.8020,00056,000217,859Jun 06 04:33 PM
BAKER BROS. ADVISORS LPDirectorMay 02Option Exercise9.9260,000595,20029,267,937May 03 04:19 PM
Hoppenot HerveChairman / CEOMay 02Buy60.9415,000914,100276,690May 03 05:05 PM
SWAIN PAULA JEVP, Human ResourcesApr 30Option Exercise17.7980,0001,423,200107,267May 02 05:04 PM
SWAIN PAULA JEVP, Human ResourcesApr 30Sale62.4380,0004,994,40033,367May 02 05:04 PM
BROOKE PAUL ADirectorApr 05Option Exercise9.9220,000198,400217,859Apr 09 05:01 PM